|
|
Article: Synthetic peptide may play key role in cancer immune therapies.
- Article from:
- Biotech Week
- Article date:
- September 29, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 SEP 29 - (NewsRx.com & NewsRx.net) -- A synthetic peptide derived from IL-10 can mimic the Ag presentation-related effects mediated by this cytokine in human melanomas and increase tumor sensitivity to NK cells, which can be relevant in the designing of future strategies for cancer immune therapy.
"Tumor cells treated with IL-10 were shown to have decreased, but peptide-inducible expression of MHC class I, decreased sensitivity to MHC class I-restricted CTL, and increased NK sensitivity," scientists in Chile report.
"These findings could be explained, at least partially, by a down-regulation of TAP1/TAP2 expression. In this study, IT9302, a ...